181 related articles for article (PubMed ID: 32982167)
1. Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody.
Huang L; Xie K; Li H; Wang R; Xu X; Chen K; Gu H; Fang J
Drug Des Devel Ther; 2020; 14():3201-3214. PubMed ID: 32982167
[TBL] [Abstract][Full Text] [Related]
2. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
3. A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer.
Li JF; Niu YY; Xing YL; Liu F
Biosci Rep; 2019 May; 39(5):. PubMed ID: 29187584
[TBL] [Abstract][Full Text] [Related]
4. A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.
Sun ZJ; Wu Y; Hou WH; Wang YX; Yuan QY; Wang HJ; Yu M
Oncotarget; 2017 Apr; 8(17):29067-29079. PubMed ID: 28404966
[TBL] [Abstract][Full Text] [Related]
5. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
[TBL] [Abstract][Full Text] [Related]
6. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
Castoldi R; Ecker V; Wiehle L; Majety M; Busl-Schuller R; Asmussen M; Nopora A; Jucknischke U; Osl F; Kobold S; Scheuer W; Venturi M; Klein C; Niederfellner G; Sustmann C
Oncogene; 2013 Dec; 32(50):5593-601. PubMed ID: 23812422
[TBL] [Abstract][Full Text] [Related]
7. Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET.
Wu Y; Yu M; Sun Z; Hou W; Wang Y; Yuan Q; Mo W
Protein Pept Lett; 2018 Feb; 24(12):1105-1112. PubMed ID: 29046141
[TBL] [Abstract][Full Text] [Related]
8. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells.
Grugan KD; Dorn K; Jarantow SW; Bushey BS; Pardinas JR; Laquerre S; Moores SL; Chiu ML
MAbs; 2017 Jan; 9(1):114-126. PubMed ID: 27786612
[TBL] [Abstract][Full Text] [Related]
9. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
[TBL] [Abstract][Full Text] [Related]
10. MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.
Casaletto JB; Geddie ML; Abu-Yousif AO; Masson K; Fulgham A; Boudot A; Maiwald T; Kearns JD; Kohli N; Su S; Razlog M; Raue A; Kalra A; Håkansson M; Logan DT; Welin M; Chattopadhyay S; Harms BD; Nielsen UB; Schoeberl B; Lugovskoy AA; MacBeath G
Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7533-7542. PubMed ID: 30898885
[TBL] [Abstract][Full Text] [Related]
11. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
Neijssen J; Cardoso RMF; Chevalier KM; Wiegman L; Valerius T; Anderson GM; Moores SL; Schuurman J; Parren PWHI; Strohl WR; Chiu ML
J Biol Chem; 2021; 296():100641. PubMed ID: 33839159
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition.
Gu CL; Zhu HX; Deng L; Meng XQ; Li K; Xu W; Zhao L; Liu YQ; Zhu ZP; Huang HM
Acta Pharmacol Sin; 2022 Mar; 43(3):672-680. PubMed ID: 33990766
[TBL] [Abstract][Full Text] [Related]
13. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.
Moores SL; Chiu ML; Bushey BS; Chevalier K; Luistro L; Dorn K; Brezski RJ; Haytko P; Kelly T; Wu SJ; Martin PL; Neijssen J; Parren PW; Schuurman J; Attar RM; Laquerre S; Lorenzi MV; Anderson GM
Cancer Res; 2016 Jul; 76(13):3942-53. PubMed ID: 27216193
[TBL] [Abstract][Full Text] [Related]
14. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
[TBL] [Abstract][Full Text] [Related]
15. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
16. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer.
Zhou Y; Zong H; Han L; Xie Y; Jiang H; Gilly J; Zhang B; Lu H; Chen J; Sun R; Pan Z; Zhu J
J Exp Clin Cancer Res; 2020 May; 39(1):87. PubMed ID: 32398042
[TBL] [Abstract][Full Text] [Related]
17. A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART
Betts A; Haddish-Berhane N; Shah DK; van der Graaf PH; Barletta F; King L; Clark T; Kamperschroer C; Root A; Hooper A; Chen X
AAPS J; 2019 May; 21(4):66. PubMed ID: 31119428
[TBL] [Abstract][Full Text] [Related]
18. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
Osada T; Patel SP; Hammond SA; Osada K; Morse MA; Lyerly HK
Cancer Immunol Immunother; 2015 Jun; 64(6):677-88. PubMed ID: 25742933
[TBL] [Abstract][Full Text] [Related]
19. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
20. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
